118 related articles for article (PubMed ID: 19434633)
21. Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation.
Singh R; Fouladi-Nashta AA; Li D; Halliday N; Barrett DA; Sinclair KD
J Cell Biochem; 2006 Sep; 99(1):146-55. PubMed ID: 16598758
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells.
Grem JL; Daychild P; Drake J; Geoffroy F; Trepel JB; Pirnia F; Allegra CJ
Biochem Pharmacol; 1994 Nov; 48(11):2117-26. PubMed ID: 7528507
[TBL] [Abstract][Full Text] [Related]
24. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.
Ewald JA; Desotelle JA; Church DR; Yang B; Huang W; Laurila TA; Jarrard DF
Prostate; 2013 Mar; 73(4):337-45. PubMed ID: 22911222
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034.
Bissett D; McLeod HL; Sheedy B; Collier M; Pithavala Y; Paradiso L; Pitsiladis M; Cassidy J
Br J Cancer; 2001 Feb; 84(3):308-12. PubMed ID: 11161393
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of CCRF-CEM human leukemic lymphoblasts by triciribine (tricyclic nucleoside, TCN, NSC-154020). Accumulation of drug in cells and comparison of effects on viability, protein synthesis and purine synthesis.
Moore EC; Hurlbert RB; Massia SP
Biochem Pharmacol; 1989 Nov; 38(22):4037-44. PubMed ID: 2480791
[TBL] [Abstract][Full Text] [Related]
28. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
[TBL] [Abstract][Full Text] [Related]
29. Cooperation between p21 and Akt is required for p53-dependent cellular senescence.
Kim YY; Jee HJ; Um JH; Kim YM; Bae SS; Yun J
Aging Cell; 2017 Oct; 16(5):1094-1103. PubMed ID: 28691365
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells.
Hasan Y; Schoenherr D; Martinez AA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):896-904. PubMed ID: 20159364
[TBL] [Abstract][Full Text] [Related]
31. Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine.
King ME; Honeysett JM; Howell SB
J Clin Invest; 1983 Sep; 72(3):965-70. PubMed ID: 6193145
[TBL] [Abstract][Full Text] [Related]
32. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents.
Girinsky T; Koumenis C; Graeber TG; Peehl DM; Giaccia AJ
Cancer Res; 1995 Sep; 55(17):3726-31. PubMed ID: 7543816
[TBL] [Abstract][Full Text] [Related]
33. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
34. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
35. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
36. Argentatin B Inhibits Proliferation of Prostate and Colon Cancer Cells by Inducing Cell Senescence.
Alcántara-Flores E; Brechú-Franco AE; García-López P; Rocha-Zavaleta L; López-Marure R; Martínez-Vázquez M
Molecules; 2015 Nov; 20(12):21125-37. PubMed ID: 26633316
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor.
Tam CW; Cheng AS; Ma RY; Yao KM; Shiu SY
Endocrinology; 2006 Nov; 147(11):5023-33. PubMed ID: 16873542
[TBL] [Abstract][Full Text] [Related]
38. Emodin induces apoptosis in human prostate cancer cell LNCaP.
Yu CX; Zhang XQ; Kang LD; Zhang PJ; Chen WW; Liu WW; Liu QW; Zhang JY
Asian J Androl; 2008 Jul; 10(4):625-34. PubMed ID: 18478162
[TBL] [Abstract][Full Text] [Related]
39. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines.
Aranda N; Sosa S; Delgado G; Aceves C; Anguiano B
Prostate; 2013 Jan; 73(1):31-41. PubMed ID: 22576883
[TBL] [Abstract][Full Text] [Related]
40. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
Lu X; Errington J; Chen VJ; Curtin NJ; Boddy AV; Newell DR
Clin Cancer Res; 2000 Jan; 6(1):271-7. PubMed ID: 10656458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
